lamivudine has been researched along with didanosine in 285 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 102 (35.79) | 18.2507 |
| 2000's | 133 (46.67) | 29.6817 |
| 2010's | 48 (16.84) | 24.3611 |
| 2020's | 2 (0.70) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ainsworth, J; Booth, C; Bradshaw, D; Geretti, AM; Malik, S; Pattery, T; Van Houtte, M; Waters, A | 1 |
| Anderson, DJ; Gottlieb, GS; Preston, BD; Pyrak, CL; Smith, RA | 1 |
| Beadle, JR; Bradley, M; Farasati, NA; Hostetler, KY; Huang, Y; Meier, C; Randhawa, P; Sauerbrei, A; Zemlicka, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Haas, RH; Naviaux, RK; Saitoh, A; Salva, NG; Spector, SA; Wong, JK | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Costa, J; Dumontet, V; Leyssen, P; Litaudon, M; Neyts, J; Nothias-Scaglia, LF; Pannecouque, C; Paolini, J; Retailleau, P; Roussi, F | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
| Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P | 1 |
| Ashok, P; Balzarini, J; Chander, S; Murugesan, S; Pannecouque, C | 1 |
| Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P | 1 |
| Girard-Valenciennes, E; Grondin, I; Leyssen, P; Litaudon, M; Neyts, J; Olivon, F; Palenzuela, H; Pannecouque, C; Roussi, F | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bhatt, HG; Pannecouque, C; Patel, BD; Patel, SB | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Chen, Z; Daelemans, D; De Clercq, E; Huang, B; Li, W; Liu, H; Liu, X; Pannecouque, C; Sun, S; Wang, X; Zhan, P | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cameron, JM; Cammack, N; Coates, JA; Jenkinson, HJ; Jowett, AJ; Jowett, MI; Pearson, BA; Penn, CR; Rouse, PL; Viner, KC | 1 |
| Portegies, P | 1 |
| Mitsuya, H | 1 |
| Cameron, J; Fang, H; Gao, Q; Goldberg, E; Gu, Z; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Arts, EJ; Fletcher, RS; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Barry, DW; Pennington, KN; Rooney, J; St Clair, MH | 1 |
| Gunnarsson, G; Hammer, SM | 1 |
| Dudley, MN | 1 |
| Boucher, C; Cameron, J; Cammack, N; Gao, Q; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Arts, EJ; Gu, Z; Le Grice, SF; Marois, JP; Wainberg, MA | 1 |
| Brenner, B; Lalonde, R; Mercure, L; Phaneuf, D; Wainberg, MA | 1 |
| Barbosa, P; Buchbinder, S; Feinberg, M; Harrer, E; Harrer, T; Johnson, RP; Walker, BD | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Costes, O; Djediouane, A; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Chikami, GK; Piazza-Hepp, TD; Styrt, BA | 1 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Lafeuillade, A; Pellegrino, P; Poggi, C; Profizi, N; Sayada, C | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Notheis, G; Sölder, B; Wintergerst, U | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Heins, JR | 1 |
| Iversen, AK; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C; Tourres, C | 1 |
| Craig, C; Moyle, G | 1 |
| Eisen, JA; Katzenstein, DA; Merigan, TC; Shafer, RW | 1 |
| Fantini, J; Lafeuillade, A; Poggi, C; Tamalet, C; Yahi, N | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Kewn, S; Veal, GJ | 1 |
| Casas, E; Gómez-Cano, M; González-Lahoz, J; Soriano, V; Valencia, E; Villalba, N | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K; Tamalet, C | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Edelstein, RE; Frenkel, LM; Manns-Arcuino, LA; Nickerson, DA; Tobe, VO | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Manion, V | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Font, E; Lasanta, S; Rodríguez, JF; Rosario, O | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Heald, AE; Pieper, CF; Schiffman, SS | 1 |
| Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, AC; Schmitt, MP | 1 |
| Saag, MS; Schooley, RT | 1 |
| Brouwers, P; Johnson, GM; Keller, A; McKinney, RE; McNamara, J; Mitchell, WG; Mofenson, L; O'Donnell, KJ; Spector, SA; Stanley, K; Wara, DW; Wiznia, A; Yogev, R; Yong, FH | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Phillips, L | 1 |
| Back, DJ; Barry, MG; Henry-Mowatt, JS; Hoggard, PG; Kewn, S; Sales, SD; Veal, GJ | 1 |
| Chêne, G; Cotte, L; Debord, T; Decazes, JM; Ferchal, F; Journot, V; Madelaine, I; Molina, JM; Pellegrin, I; Rancinan, C; Sombardier, MN | 1 |
| Bassett, R; Bell, D; Eron, JJ; Fife, K; Fischl, MA; Johnson, VA; Kuritzkes, DR; Maenza, J; Marschner, I; Murphy, RL; Pettinelli, C; Rosandich, ME; Sommadossi, JP; Wood, K | 1 |
| Ahmad, M; Brennan, JM; Caliendo, AM; Fiske, WD; Flanigan, TP; Gormley, JM; Tashima, KT | 1 |
| Aleman, S; Loré, K; Sönnerborg, A; Visco-Comandini, U | 1 |
| Ahrens, P; Funk, MB; Hoffmann, F; Kornhuber, B; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Gendelman, HE; Lanier, ER; Limoges, J; McClernon, DR; Persidsky, Y; Poluektova, L; Rasmussen, J; Ratanasuwan, W; Zelivyanskaya, M | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Puig, T; Rey, C; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Campi, G; Casorati, G; Corey, L; Demarest, JF; Kaufmann, D; Lazzarin, A; Lenge, C; Pantaleo, G; Rizzardi, GP; Soudeyns, H; Tambussi, G | 1 |
| Andreotti, M; Bricalli, D; Clerici, M; Dally, LG; Di Fabio, S; Ferrante, P; Pirillo, M; Principi, N; Saresella, M; Vanzulli, A; Vella, S; Vigano, A | 1 |
| Clumeck, N | 1 |
| Carlebach, A; Gute, P; Haberl, A; Miller, V; Nisius, G; Staszewski, S | 1 |
| Anderson, RD | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Boschini, A; Calista, D | 1 |
| Bray, D; Clerici, M; Colombo, F; Dix, LP; Fusi, ML; Milazzo, F; Piconi, S; Rizzardini, G; Trabattoni, D | 1 |
| Carr, A; Chuah, J; Cooper, DA; Emery, S; French, M; Hoy, J; Hudson, J; Law, M; Sayer, D | 1 |
| Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W | 1 |
| James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB | 1 |
| Ahmed, PS; Bedard, J; Bowlin, TL; Chambers, P; Clarke, J; Kelly, LA; Rando, RF; Taylor, DL; Tyms, AS; Wood, LJ | 1 |
| Bellos, N; Eron, JJ; Esinhart, J; Grosso, R; Jemsek, J; Murphy, RL; Parenti, DM; Peterson, D; Pottage, J; Rashbaum, BC; Schoellkopf, N; Sepulveda, G; Stevens, M; Swindells, S | 1 |
| Badia, X; Benavides, A; Coma, A; López Lavid, C; Pinto, JL | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| Pozo, F; Rivero, A; Serrano, R; Tenorio, A; Torre-Cisneros, J; Vidal, E | 1 |
| Boers, PH; Gruters, RA; Guillon, C; Ly, TD; Osterhaus, AD; Schutten, M; van der Ende, ME | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Fiore, TC; Tashima, KT | 1 |
| Brown, T; Feingold, AR; Meislich, D; Rudy, BJ; Rutstein, RM | 1 |
| Albrecht, M; Balfour, H; Hammer, S; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, M | 1 |
| Bamberger, JD; Chambers, D; Chesney, M; Coates, TJ; Franses, K; Kahn, JO; Katz, MH; Martin, JN; Roland, ME | 1 |
| Autran, B; Carcelain, G; Damond, F; Dehée, A; Delphin, N; Girard, PM; Jacomet, C; Mariot, P; Nicolas, JC; Rozenbaum, W; Saimot, AG; Schneider, V | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Arazo, P; Manero, FJ; Sesma, J | 1 |
| Anderson, RM; Cane, PA; Ferguson, NM; Pillay, D; Taylor, S | 1 |
| Angelosante, W; Carneiro, M; Maneiro, P; Pérez, C; Sanchéz, A; Valleé, M | 1 |
| Ahrlund-Richter, L; Britton, S; Larsson, S; Maijgren-Steffensson, C; Sönnerborg, A; Vahlne, A | 1 |
| Gilden, D | 1 |
| Poscher, M | 2 |
| Japour, AJ | 1 |
| Levin, J | 1 |
| Smart, T | 3 |
| James, JS | 4 |
| Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C | 1 |
| Alcorn, K | 1 |
| Cooper, EC | 1 |
| Torres, G | 1 |
| Falkenberg, J; Gilden, D; Torres, G | 1 |
| Doepel, L; Folkers, G | 1 |
| Cadman, J | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| Amaro, J; Bienvenu, L; Burel, F; Hofman, P; Hofman, V; Itchaï, C | 1 |
| Buranapraditkun, S; Cooper, DA; Kroon, ED; Kunanusont, C; Lange, JM; Pakker, N; Phanuphak, P; Ruxrungtham, K; Sonjai, A; Suwanagool, S; Tiengrim, S; Ubolyam, S; Ungsedhapand, C; Yimsuan, N | 1 |
| Bulgheroni, E; Citterio, P; Croce, F; Galazzi, M; Galli, M; Kurtagic, S; La Seta Catamancio, S; Moroni, M; Rusconi, S | 1 |
| Corzo, JE; Gómez-Mateos , J; Lozano, F; Ramayo, E | 1 |
| Holodniy, M; Mole, L; Schmidgall, D | 1 |
| Angelini, E; Chêne, G; Clavel, F; Ferchal, F; Maillard, A; Molina, JM; Picard, V; Race, E | 1 |
| Aaron, L; Carnot, F; Pialoux, G | 1 |
| Cain, D; Clarke, JR; Erlwein, O; Frater, AJ; Grigg, AR; Hill, CL; McClure, MO; Patton, G; Rosenblum, LL | 1 |
| Chadapaud, S; Chouraqui, M; Delbeke, E; Hittinger, G; Lafeuillade, A; Poggi, C | 1 |
| Chadapaud, S; Halfon, P; Hittinger, G; Khiri, H; Lafeuillade, A; Poggi, C | 1 |
| Carlebach, A; Gute, P; Haberl, A; Miller, V; Rottmann, C; Staszewski, S | 1 |
| Altisent, C; Briones, C; Domingo, E; Mas, A; Pérez-Olmeda, M; Soriano, V | 1 |
| Delaporte, E; Malonga-Mouellet, G; Mansaray, H; Mavoungou, R; Mistoul, I; Peeters, M; Vergne, L | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| Becher, F; Benech, H; Delfraissy, JF; Goujard, C; Grassi, J; Guerreiro, C; Pruvost, A | 1 |
| Maggiolo, F; Maserati, R; Migliorino, M; Pan, A; Provettoni, G; Rizzi, L; Rizzi, M; Suter, F | 1 |
| Klinowska-Skupniewska, J; Prandota-Schoepp, A | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Aldamiz-Etxebarría, M; Andonegui Navarro, J | 1 |
| Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Baldanti, F; Galloni, D; Gerna, G; Lilleri, D; Piccinini, G; Seminari, E | 1 |
| Estrela, Rde C; Raices, RS; Salvadori, MC; Suarez-Kurtz, G | 1 |
| Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
| Bachiller Luque, P; de Luis Román, DA; Eiros Bouza, JM; Ortega Lafont, M; Ortiz de Lejarazu, R | 1 |
| Das, P | 1 |
| Albrecht, MA; Bosch, RJ; Katzenstein, DA; Winters, MA | 1 |
| Baba, M; Nitanda, T; Somekawa, K; Wang, X; Yuasa, S | 1 |
| Chuenyam, T; Cooper, D; Emery, S; Lange, J; Phanuphak, P; Ruxrungtham, K; Sirivichayakul, S; Techasathit, W; Ubolyam, S; Ungsedhapand, C | 1 |
| Macher, A; Paul, SM; Thomas, D | 1 |
| Barber, RE; Lonergan, JT; Mathews, WC | 1 |
| Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
| D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
| Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L | 1 |
| Boyle, BA | 1 |
| Cardellach, F; Casademont, J; García-Viejo, MA; Gatell, JM; López, S; Martínez, E; Milinkovic, A; Miró, O; Nunes, V; Pedrol, E; Rodríguez-Santiago, B; Soler, A | 1 |
| Baseler, M; Beck, I; Coffin, J; Daucher, M; Davey, RT; Dewar, R; Dybul, M; Ehler, L; Fauci, AS; Frenkel, L; Hallahan, CW; Maldarelli, F; Metcalf, JA; Nies-Kraske, E; Palmer, S; Piscitelli, SC; Powers, A; Rock Kress, DM; Weigand, A | 1 |
| Cardiello, P; Cooper, DA; Emery, S; Juengprasert, N; Kroon, ED; Lange, JM; Phanuphak, P; Ratanasuwan, W; Ruxrungtham, K; Siangphoe, U; Srasuebkul, P; Tongtalung, M; Ubolyam, S; Ungsedhapand, C | 1 |
| Fisher, M | 1 |
| Cassol, S; El-Sadr, W; Friedland, G; Jack, C; Karim, QA; Karim, SA; Lalloo, U | 1 |
| Rosa, U; Sepkowitz, D; Smith, PR; Tripuraneni, NS; Weedon, J | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
| Aarnoutse, RE; Burger, DM; Verweij-van Wissen, CP | 1 |
| Bartsch, G; El-Sadr, WM; Gibert, C; Grunfeld, C; Kotler, D; Peng, G; Raghavan, S; Shlay, JC; Visnegarwala, F; Wang, J | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Chêuc, G; Cotte, L; Debord, T; Decazes, JM; Ferchal, F; Journot, V; Madelaine, I; Molina, JM; Pellegrin, I; Rancinan, C; Sombardier, MN | 1 |
| Lewis, W | 1 |
| Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A | 1 |
| Alston-Smith, BL; Dubé, MP; Kitch, DW; Mulligan, K; Parker, RA | 1 |
| Alhassoon, OM; Brown, GG; Ellis, RJ; Gonzalez, R; Grant, I; Letendre, S; McCutchan, JA; Patterson, TL; Schweinsburg, BC; Taylor, MJ; Videen, JS | 1 |
| Azuaje, C; Domingo, P; Falco, V; Gatell, JM; Lopez, RM; Lopez-Colomes, JL; Mallolas, J; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Sambea, MA; Sánchez, P; Soriano, A | 1 |
| Ballardin, M; Barale, R; Kotwal, GJ; Scarpato, R | 1 |
| Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J | 1 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| de Baar, MP; de Ronde, A; Ruiter, JP; Tebas, P; Timmermans, EC; Wanders, RJ | 1 |
| Amiel, C; Guessant, S; Kara, A; Lebrette, MG; Marechal, Eda S; Pialoux, G; Quercia, R; Renaud, S; Schneider, V; Thevenet, S | 1 |
| Brenner, BG; Doualla-Bell, F; Essex, M; Frankel, F; Moisi, DD; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Friedland, G; Jack, C; Khoo, S; Lalloo, U | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Amellal, B; Calvez, V; Castro, ND; Chêne, G; Cotte, L; Gourlain, K; Journot, V; Molina, JM; Palmer, P; Pédrono, G; Rancinan, C | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Pajkrt, D; Scherpbier, HJ | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| Bettendorf, D; Bosch, RJ; Eron, JJ; Fiscus, S; Frank, I; Petch, L | 1 |
| Dubé, MP; Grinspoon, SK; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Bergroth, T; Lidman, K; Sönnerborg, A; Svedhem, V | 1 |
| Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V | 1 |
| de la Torres, J; Gálvez, MC; López, M; López-Cortés, LF; Lozano, F; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
| Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
| Ahmadou Ahidjo, B; Becker, P; Dusé, AG; Marais, E; Veale, R | 1 |
| Cao, YL; Guo, Y | 1 |
| Braude, J; Galambos, MR; Joelson, D; Johnson, M; Rubin, RA; Saifee, S; Sellers, M; Shrestha, R | 1 |
| Angels Ribas, M; Asensi, V; Berenguer, J; Domingo, P; Gimeno, JL; González, J; Miralles, P; Pedrol, E; Pérez-Molina, JA; Ribera, E; Santamaría, JM; Santos, J; Terrón, JA | 1 |
| Berrisford, AE; Boulle, AM; Jaspan, HB | 1 |
| Aste, N; Atzori, L; Ferreli, C; Pau, M; Pilloni, L; Pinna, AL | 1 |
| Cosin, J; Crespo, M; Domingo, P; Galindo, MJ; García-Alcalde, ML; Garrido, M; Geijo, P; López-Aldeguer, J; Lozano, F; Muñoz, A; Pedrol, E; Ribera, E; Roca, B; Sánchez, T; Suárez-Lozano, I; Teira, R; Terrón, A; Vergara, A; Viciana, P; Vidal, F; Viladés, C | 1 |
| Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
| Ishikawa, H; Kaneko, S; Katayama, M; Matsuda, Y; Miyaji, K; Suzuki, K; Takamatsu, K | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| Afonso, AO; Cunha, SM; Lemey, P; Machado, ES; Nissley, DV; Oliveira, RH; Soares, MA | 1 |
| Olivero, OA; Poirier, MC; Ward, Y; Yu, M | 1 |
| Beltrame, A; Bozzano, F; Cenderello, G; Costa, P; De Maria, A; Di Biagio, A; Fenoglio, D; Ferrea, G; Pagano, G | 1 |
| Karunaianantham, R; Narayanan, PR; Rajesh, L; Swaminathan, S | 1 |
| Chang, Y; Fu, Q; He, Z; Meng, P; Sun, J; Sun, Y; Wang, J; Xu, Y; Yan, Z; Zhu, M | 1 |
| Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Campo, RE; Cohen, C; Grimm, K; Maa, J; Seekins, D; Shangguan, T | 1 |
| Benalycherif, A; Bennai, Y; Diallo, MB; Fall, MB; Girard, PM; Gueye, NF; Kane, CT; Landman, R; Mboup, S; Ndiaye, B; Peytavin, G; Sow, PS | 1 |
| Bichet, JC; Delfraissy, JF; Ghosn, J; Sahali, S | 1 |
| Bardin, C; Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E | 1 |
| Barnas, D; Bazmi, H; Bixby, C; Jemsek, J; Koontz, D; Mellors, JW | 1 |
| Cook, A; Divi, RL; Einem, TL; Fletcher, SL; Harbaugh, JW; Harbaugh, SW; Kuo, MM; Nagashima, K; Poirier, MC; Shockley, ME; St Claire, MC | 1 |
| Feng, Y; Huang, J; Huang, Y; Liao, L; Liu, S; Ma, L; Qu, S; Shao, Y; Sun, J; Xing, H; Yu, X; Yuan, L | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
| Crane, HM; Feldman, BJ; Grunfeld, C; Kitahata, MM; Lederman, MM; Moore, R; Mugavero, MJ; Rodriguez, B; Saag, MS; Van Rompaey, S; Willig, JH | 1 |
| Emery, S; Hu, Z; Khabo, P; Maja, P; Manzini, P; Matchaba, G; Matthews, GV; Metcalf, J; Orsega, S; Pool, N; Sangweni, P | 1 |
| Barro, M; Diagbouga, S; Diasso, Y; Drabo, A; Foulongne, V; François, R; Hien, A; Hien, H; Michel, S; Msellati, P; Nacro, B; Ouiminga, A; Some, J; Tamboura, H; Van De Perre, P; Yaméogo, S; Zouré, E | 1 |
| Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR | 1 |
| Chang, HM; Chen, YS; Lee, SS; Tsai, HC; Wann, SR | 1 |
| Cunha, KS; de Andrade, HH; Dihl, RR; Guimarães, NN; Lehmann, M; Silva, CJ | 1 |
| Campbell, GR; Pallack, ZT; Spector, SA | 1 |
| Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van de Perre, P; Zoure, E | 1 |
| Chappuy, H; Diagbouga, S; Drabo, A; Hien, A; Hien, H; Meda, N; Msellati, P; Nacro, B; Nicolas, J; Ouiminga, A; Rouet, F; Somé, J; Tamboura, H; Van de Perre, P; Yaméogo, S; Zoure, E | 1 |
| Chen, D; Chen, X; Ding, W; Gao, Z; Jin, R; Qiao, L; Song, F; Yang, S; Zhang, Y | 1 |
| Dziuban, EJ; Koumans, EH; Raizes, E | 1 |
| Che, J; Chen, X; Cheng, Y; Dong, T; Meng, Q; Qian, X; Tong, B | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Chen, D; Chen, J; Guo, H; Liang, Q; Qiao, L; Wang, B; Wu, J; Xu, B; Yang, S; Zhang, H; Zhang, Y | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Arellano, J; Corredoira, Y; Gonzalez, R; Nuñez, R | 1 |
| Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P | 1 |
| Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT | 1 |
21 review(s) available for lamivudine and didanosine
| Article | Year |
|---|---|
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Clinical toxicity of antiretroviral nucleoside analogs.
Topics: Animals; Antiviral Agents; Didanosine; Humans; Lamivudine; Mitochondria; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
The development of resistance of HIV-1 to zalcitabine.
Topics: Amino Acids; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Zalcitabine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1998 |
Contraindicated antiretroviral drug combinations.
Topics: Anti-Retroviral Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zalcitabine | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
Topics: Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Randomized Controlled Trials as Topic; Stavudine; Viral Load | 1998 |
Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature.
Topics: Acidosis, Lactic; Adult; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; New York; Reverse Transcriptase Inhibitors; Stavudine; Syndrome; Zidovudine | 2004 |
Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; DNA Replication; DNA, Mitochondrial; Humans; Lamivudine; Mitochondria; Nucleosides; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2005 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
Topics: Aged, 80 and over; Antiretroviral Therapy, Highly Active; Ascites; Chemical and Drug Induced Liver Injury; Didanosine; Fatal Outcome; HIV Infections; HIV-1; Humans; Hypertension, Portal; Lamivudine; Male; Nevirapine; Portal Vein; Thrombosis; Tomography, X-Ray Computed | 2012 |
76 trial(s) available for lamivudine and didanosine
| Article | Year |
|---|---|
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4-CD8 Ratio; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocytes; Male; Pilot Projects; Proviruses; RNA, Viral; Zidovudine | 1997 |
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay.
Topics: Adult; Anti-HIV Agents; Colorimetry; Didanosine; DNA, Viral; Evaluation Studies as Topic; Female; HIV-1; Humans; Indinavir; Lamivudine; Male; Polymerase Chain Reaction; Proviruses; Ritonavir; RNA, Viral; Transcription, Genetic; Zalcitabine; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
Topics: Adolescent; Anti-HIV Agents; CD4 Antigens; Child; Child, Preschool; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Neurodegenerative Diseases; Polymerase Chain Reaction; RNA, Viral; Survival Rate; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viremia; Zidovudine | 1999 |
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Invest
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load; Zidovudine | 1999 |
Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Viral Load; Zidovudine | 1999 |
Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Data Interpretation, Statistical; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Stavudine; Time Factors; Zidovudine | 1999 |
Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Methadone; Nevirapine; Pilot Projects; Prospective Studies; Substance Abuse, Intravenous; Viral Load | 1998 |
Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine | 1998 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection.
Topics: Anti-HIV Agents; Apoptosis; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cytokines; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Prospective Studies; Reverse Transcriptase Inhibitors; Th1 Cells; Viremia; Zidovudine | 2000 |
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Stavudine; Viral Load; Zidovudine | 2000 |
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Female; Germany; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; White People | 2000 |
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; Stavudine; Thymidine; Viral Load; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Daunorubicin; Didanosine; Drug Therapy, Combination; Herpesvirus 8, Human; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Sarcoma, Kaposi; Stavudine; Viremia | 2000 |
Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2001 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
Research study of combination AIDS therapies underway.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Nevirapine; Pyridines; Zidovudine | 1996 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Major pediatric study stopped early: combination treatment better.
Topics: Anti-HIV Agents; Child; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine | 1997 |
Combination therapies improve outlook for children with HIV disease.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine | 1997 |
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Thailand; Treatment Outcome; Zidovudine | 2001 |
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymph Nodes; Lymphocyte Subsets; Lymphocytes; Male; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Viral Load; Viremia; Virus Replication | 2001 |
Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Progression; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Morbidity; Prognosis; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 2001 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Determination of didanosine in human serum by on-line solid-phase extraction coupled to high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study.
Topics: Administration, Oral; Calibration; Chromatography, High Pressure Liquid; Didanosine; Humans; Lamivudine; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Therapeutic Equivalency | 2003 |
Feeding risk cut for HIV-infected women.
Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Rwanda; Uganda; Zidovudine | 2003 |
Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Proportional Hazards Models; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2003 |
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
Topics: Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; Cholesterol; Cyclopropanes; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Polymerase Chain Reaction; RNA, Viral; Triglycerides | 2004 |
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Stavudine; Thailand; Time Factors; Zidovudine | 2004 |
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Outpatient Clinics, Hospital; Oxazines; Pilot Projects; South Africa; Treatment Outcome; Tuberculosis; Urban Population | 2004 |
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.
Topics: Adult; Anti-HIV Agents; Body Composition; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Stavudine | 2005 |
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 1999 |
Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Pilot Projects; RNA, Viral; Spain | 2005 |
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aspartic Acid; Brain; Cell Respiration; Didanosine; Female; HIV Infections; Humans; Lamivudine; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2005 |
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Saquinavir; Spain; Treatment Outcome; Tuberculosis | 2005 |
[Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Disease Progression; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine; Zidovudine | 2006 |
Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.
Topics: Adult; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Leukocytes, Mononuclear; Logistic Models; Male; Reverse Transcriptase Inhibitors; Stavudine; Surveys and Questionnaires; Time Factors; Zidovudine | 2007 |
The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Point Mutation | 2007 |
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Didanosine; Double-Blind Method; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Nelfinavir; Prospective Studies; Stavudine; Testosterone; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Spain; Treatment Outcome | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Tuberculosis | 2009 |
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Culture; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Zidovudine | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Patient Compliance; Patient Satisfaction; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; United States; Viral Load | 2010 |
Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Senegal; Treatment Outcome | 2010 |
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
Topics: Adolescent; Africa, Western; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Treatment Outcome | 2010 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.
Topics: Adult; Africa, Southern; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; CD4 Lymphocyte Count; Didanosine; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Stavudine; Treatment Outcome | 2011 |
Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Viral Load | 2011 |
A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Models, Theoretical; Predictive Value of Tests; Treatment Failure; Viral Load | 2013 |
24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Surveys and Questionnaires; Viral Load | 2013 |
Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Double-Blind Method; Drug Combinations; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Peptide Fragments; Peptides; Ritonavir | 2014 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
188 other study(ies) available for lamivudine and didanosine
| Article | Year |
|---|---|
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2007 |
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
Topics: Anti-HIV Agents; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Anti-BK virus activity of nucleoside analogs.
Topics: Adenine; BK Virus; Esters; Fatty Acids; Humans; Microbial Sensitivity Tests; Nucleosides; Organophosphonates; Virus Replication | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
Topics: Cell Proliferation; Cells, Cultured; Dideoxynucleosides; DNA, Mitochondrial; Humans; Lamivudine; Muscle Fibers, Skeletal; Muscle, Skeletal; Myoblasts; Nucleosides; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial; Stavudine; Zidovudine | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
Topics: Alphavirus Infections; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Diterpenes; Euphorbia; France; HIV-1; HIV-2; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Semliki forest virus; Sindbis Virus; Structure-Activity Relationship; Virus Replication | 2014 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones | 2015 |
Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
Topics: Carbolines; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
Topics: Antiviral Agents; Chikungunya virus; Diterpenes; Euphorbiaceae; France; HCT116 Cells; HIV-1; HIV-2; Humans; Macrocyclic Compounds; MCF-7 Cells; Molecular Structure; Semliki forest virus; Sindbis Virus; Virus Replication | 2015 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.
Topics: Animals; Anti-HIV Agents; Chlorocebus aethiops; Computer Simulation; Drug Design; HIV Integrase; Molecular Docking Simulation; Quantitative Structure-Activity Relationship; Quinoxalines; Vero Cells | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.
Topics: Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfones | 2017 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Topics: Cell Death; Cells, Cultured; Didanosine; Giant Cells; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; RNA-Directed DNA Polymerase; Tritium; Virus Replication; Zalcitabine; Zidovudine | 1992 |
HIV-1, the brain, and combination therapy.
Topics: Adult; AIDS Dementia Complex; Antiviral Agents; Child; Didanosine; Drug Combinations; HIV-1; Humans; Lamivudine; Neuroprotective Agents; Stavudine; Zalcitabine; Zidovudine | 1995 |
[AIDS therapy with reverse transcriptase inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1993 |
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Codon; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cloning, Molecular; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Kinetics; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Polynucleotides; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Substrate Specificity; Templates, Genetic; Zalcitabine | 1994 |
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Topics: Antiviral Agents; Base Sequence; Cloning, Molecular; Didanosine; Drug Resistance, Microbial; HIV-1; Humans; Lamivudine; Methionine; Mutagenesis, Site-Directed; Mutation; Stereoisomerism; Valine; Zalcitabine | 1993 |
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Topics: Antiviral Agents; Base Sequence; Cells, Cultured; Didanosine; Dideoxynucleotides; DNA, Viral; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Nucleic Acid Conformation; Nucleosides; Nucleotides; Phytohemagglutinins; RNA, Viral; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 1996 |
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Cell Division; Didanosine; Humans; Interleukin-2; Lamivudine; Lymphocyte Activation; Zalcitabine; Zidovudine | 1994 |
Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Conserved Sequence; Deoxycytidine; Didanosine; DNA Primers; Drug Resistance, Microbial; Epitopes; HIV Infections; HIV Reverse Transcriptase; HIV-1; HLA-A2 Antigen; Humans; Lamivudine; Molecular Sequence Data; Oligopeptides; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; T-Lymphocytes, Cytotoxic; Zalcitabine | 1996 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymph Nodes; Male; Plasma; RNA, Viral; Time Factors; Zidovudine | 1996 |
Focusing on the second phase of plasma HIV-1 RNA clearance.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Virus Replication; Zidovudine | 1997 |
Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; RNA, Viral; Time Factors; Viral Load; Viremia; Zidovudine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
Topics: Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; Drug Interactions; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1996 |
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
Topics: Adult; Amino Acid Sequence; Base Sequence; Didanosine; DNA, Viral; Female; Genes, env; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Nevirapine; Nucleic Acid Heteroduplexes; Phylogeny; Pyridines; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Zidovudine; Zimbabwe | 1997 |
Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymph Nodes; Male; Polymerase Chain Reaction; RNA, Viral; Saquinavir; Viral Load; Viremia; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymphoid Tissue; Male; RNA, Viral; Zidovudine | 1997 |
Lamivudine (3TC) phosphorylation and drug interactions in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Lymphocyte Activation; Lymphocytes; Mitogens; Models, Chemical; Monocytes; Phosphorylation; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Genes, pol; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oligonucleotide Probes; Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA; Zidovudine | 1998 |
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. The European Collaborative Study.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cohort Studies; Didanosine; Europe; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Prospective Studies; Risk Factors; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
Analysis of antiretroviral nucleosides by electrospray ionization mass spectrometry and collision induced dissociation.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Gas Chromatography-Mass Spectrometry; Lamivudine; Models, Chemical; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Secondary Ion; Zalcitabine; Zidovudine | 1998 |
Taste and smell complaints in HIV-infected patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Clarithromycin; Didanosine; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Quality of Life; Ritonavir; Smell; Surveys and Questionnaires; Taste; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1998 |
[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro.
Topics: Anti-HIV Agents; Deoxyadenine Nucleotides; Didanosine; Dideoxynucleotides; Drug Interactions; Guanosine; Humans; Hydroxyurea; Inosine; Intracellular Fluid; Lamivudine; Pentoxifylline; Stavudine; U937 Cells; Zidovudine | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
Topics: AIDS Dementia Complex; Animals; Cells, Cultured; Didanosine; Dideoxynucleosides; Disease Models, Animal; HIV-1; Humans; Lamivudine; Male; Mice; Mice, SCID; Monocytes; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zidovudine | 2000 |
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Genes, pol; Genotype; HIV-1; Humans; Lamivudine; Point Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.
Topics: Acute Disease; Anti-HIV Agents; Clone Cells; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Saquinavir; T-Lymphocytes, Cytotoxic; Viremia; Zidovudine | 2000 |
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Cohort Studies; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Organ Size; Reverse Transcriptase Inhibitors; Stavudine; Thymus Gland; Viral Load; Zidovudine | 2000 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV Wasting Syndrome; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Time Factors; Zidovudine | 2000 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Molecular Structure; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; T-Lymphocytes; Thionucleosides; Zidovudine | 2000 |
[Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Sickness Impact Profile; Spain; Stavudine; Viral Load; Zidovudine | 2000 |
Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.
Topics: Adult; Amino Acid Sequence; Consensus Sequence; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genes, Viral; Genotype; HIV Infections; HIV-2; Humans; Lamivudine; Male; Molecular Sequence Data; Phenotype; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Sustained responses to dual nucleoside therapy in women.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 2000 |
Protease inhibitor therapy in HIV-infected children.
Topics: Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Patient Compliance; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Contact Tracing; Counseling; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexually Transmitted Diseases, Viral; Substance Abuse, Intravenous; Time Factors; Zidovudine | 2001 |
Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2001 |
[Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors].
Topics: Aged; Antiretroviral Therapy, Highly Active; Dexamethasone; Didanosine; Femur Head Necrosis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Prednisone; Zidovudine | 2001 |
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Didanosine; Environmental Monitoring; HIV Infections; HIV-1; Humans; Hydroxyurea; Lamivudine; Male; Oxazines; Semen; Time Factors; Viral Load | 2001 |
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Viral Load; Zidovudine | 2001 |
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Catalytic; T-Lymphocytes; Time Factors | 2001 |
Research study of combination AIDS therapies underway.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Zidovudine | 1996 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Approval; Drug Combinations; Drug Therapy, Combination; Health Services Accessibility; Humans; Insurance, Health; Lamivudine; Managed Care Programs; United States; Zalcitabine; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
FDA triple header. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Mutation; Quinolines; Salvage Therapy; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; HIV; Humans; Lamivudine; Practice Patterns, Physicians'; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Europe out of step with the US.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Back to the nukes.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; Oxazines; Stavudine; Viral Load; Zidovudine | 1997 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Combo therapy for children and adolescents.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine | 1997 |
Reevaluating initial therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Polymerase Chain Reaction; Stavudine; Viral Load; Zidovudine | 1998 |
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.
Topics: Anti-HIV Agents; Didanosine; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine | 2001 |
[A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues].
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antimetabolites; Didanosine; Fatal Outcome; Fatty Liver; Female; HIV Seropositivity; Humans; Lamivudine; Microscopy, Electron; Mitochondria, Liver; Stavudine; Zidovudine | 2001 |
Choosing which nuke to use first.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine | 2001 |
[Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs].
Topics: Adult; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Lactic Acid; Lamivudine; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Didanosine; Drug Evaluation; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Safety; Treatment Outcome; Triglycerides; Viral Load | 2001 |
[HIV-HBV coinfection and the liver].
Topics: Biopsy; Didanosine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Ritonavir; Saquinavir; Stavudine | 2001 |
Differential susceptibility of retroviruses to nucleoside analogues.
Topics: Animals; Antiviral Agents; Cell Line; Cricetinae; Didanosine; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Lamivudine; Mink; Nucleosides; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Zalcitabine; Zidovudine | 2001 |
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pilot Projects; Polymerase Chain Reaction; RNA, Viral; Substance Abuse, Intravenous; Treatment Refusal; Viral Load | 2000 |
Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Genetic Heterogeneity; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutagenesis; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zidovudine | 2001 |
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.
Topics: Anti-HIV Agents; Developing Countries; Didanosine; Drug Resistance, Viral; Gabon; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Population Surveillance; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2002 |
Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Drug Monitoring; Humans; Lamivudine; Mass Spectrometry; Monocytes; Phosphorylation; Stavudine | 2002 |
Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; RNA, Viral | 2001 |
[Drug combination therapy for children infected with HIV/AIDS--own experience].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Poland; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
[Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Didanosine; Ganciclovir; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Retinal Hemorrhage; Reverse Transcriptase Inhibitors; Risk; Saquinavir; Stavudine; Substance Abuse, Intravenous; Zidovudine | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytomegalovirus Retinitis; Didanosine; Follow-Up Studies; Ganciclovir; HIV Protease Inhibitors; Humans; Lamivudine; Lymphocyte Activation; Male; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
[Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Didanosine; Drug Evaluation; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Topics: Anti-HIV Agents; Cell Line; Didanosine; Drug Combinations; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Nucleosides; Reverse Transcriptase Inhibitors; Stavudine; Uracil; Virus Replication | 2001 |
Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Zidovudine | 2003 |
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Stavudine; Zidovudine | 2003 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studies; Didanosine; DNA Primers; DNA, Mitochondrial; Female; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Nelfinavir; Nevirapine; Polymerase Chain Reaction; Stavudine | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; Cohort Studies; Didanosine; Drug Administration Schedule; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Viral Load; Zidovudine | 2004 |
Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2004 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Drug Stability; HIV; HIV Infections; Humans; Lamivudine; Quality Control; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Blood Preservation; Blood Specimen Collection; Didanosine; HIV Infections; Humans; Lactates; Lamivudine; Multicenter Studies as Topic; Oxalates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sodium Fluoride; Specimen Handling; Stavudine; Time Factors; Zidovudine | 2005 |
In vitro mutagenicity studies of the antiretrovirals AZT, Didanosine, and 3TC and a plant antiviral extract Secomet-V derived from the Trifollium species.
Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Lamivudine; Mutagenicity Tests; Phytotherapy; Plant Extracts; Salmonella; Trifolium; Zidovudine | 2005 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.
Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Feasibility Studies; Fibroblasts; HIV Infections; Humans; Indinavir; Lactic Acid; Lamivudine; Leukocytes, Mononuclear; Nucleic Acid Amplification Techniques; Pyruvic Acid; Stavudine; Zalcitabine | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
Topics: Adenine; Didanosine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Genetic Variation; Genotype; HIV-1; Humans; Inhibitory Concentration 50; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Tenofovir; Time Factors | 2006 |
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary; Viral Load | 2006 |
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child Development; Child, Preschool; Cholesterol; Cohort Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Oxazines; Patient Compliance; Prospective Studies; Treatment Outcome | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure.
Topics: Adult; Aged; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA-Directed DNA Polymerase; Treatment Failure; Viral Load | 2007 |
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load | 2007 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
The nucleoside reverse transcriptase inhibitors didanosine, lamivudine, stavudine and zidovudine show little effect on the virulence of Candida albicans in vitro.
Topics: Antifungal Agents; Biofilms; Candida albicans; Cell Adhesion; Cell Line; Didanosine; Humans; Lamivudine; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Stavudine; Virulence; Zidovudine | 2008 |
[Screening of HIV-1 replication inhibitors by using pseudotyped virus system].
Topics: Anti-HIV Agents; Didanosine; DNA Replication; Drug Evaluation, Preclinical; Genes, Reporter; HIV-1; Humans; Lamivudine; Pseudocowpox Virus; Tumor Cells, Cultured; Virus Replication; Zidovudine | 2008 |
Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; HIV-1; Humans; Hypertension, Portal; Lamivudine; Male; Middle Aged; Risk Factors; Thrombophilia; Viral Load; Zidovudine | 2008 |
Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Lopinavir; Male; Multivariate Analysis; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2008 |
Bullous skin eruption in an HIV patient during antiretroviral drugs therapy.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nelfinavir; Skin Diseases, Vesiculobullous | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Electrochemical Techniques; Fluorescence; Humans; Lamivudine; Linear Models; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Water; Zidovudine | 2009 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
Topics: Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation, Missense; Nelfinavir; Phylogeny; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic; Zidovudine | 2009 |
Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosine.
Topics: Animals; Centrosome; CHO Cells; Cricetinae; Cricetulus; Didanosine; Dose-Response Relationship, Drug; Gene Amplification; Humans; Lamivudine; Microscopy, Fluorescence; Reverse Transcriptase Inhibitors; Stavudine | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Killer Cells, Natural; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; T-Lymphocytes; Tenofovir | 2009 |
Simultaneous determination of didanosine and its amino acid prodrug, valdidanosine by hydrophilic interaction chromatography coupled with electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study in rats.
Topics: Administration, Oral; Amino Acids; Animals; Chromatography, Liquid; Didanosine; Drug Stability; Lamivudine; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Valine | 2010 |
Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma?
Topics: Alkynes; Benzoxazines; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating; Cyclopropanes; Didanosine; Drug Therapy, Combination; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2010 |
Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs).
Topics: Animals; Animals, Newborn; Cerebral Cortex; Didanosine; Disease Models, Animal; DNA, Mitochondrial; Drug Therapy, Combination; Erythrocebus patas; Female; Lamivudine; Maternal Exposure; Mitochondria, Liver; Oxidative Phosphorylation; Pregnancy; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2010 |
Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces.
Topics: Adult; Anti-HIV Agents; Blood Donors; China; Didanosine; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Phenotype; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Sequence Analysis, RNA; Stavudine; Zidovudine | 2010 |
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Didanosine; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Stavudine | 2011 |
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2011 |
Comparative analysis of genetic toxicity of antiretroviral combinations in somatic cells of Drosophila melanogaster.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA Damage; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Combinations; Female; Lamivudine; Male; Mitosis; Mutation; Recombinant Proteins; Wings, Animal; Zidovudine | 2013 |
Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
Topics: Anti-HIV Agents; Calcitriol; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; HIV Reverse Transcriptase; Humans; Infant; Lamivudine; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Myoblasts; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Stavudine; Vitamins; Zidovudine | 2013 |
Long-term exposure of mice to nucleoside analogues disrupts mitochondrial DNA maintenance in cortical neurons.
Topics: Animals; Antimetabolites; Cells, Cultured; Cerebral Cortex; Didanosine; DNA, Mitochondrial; Lamivudine; Liver; Mice; Mitochondria; Muscle, Skeletal; Neurons; Stavudine; Zidovudine | 2014 |
A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine.
Topics: Cost Savings; Didanosine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Harm Reduction; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2015 |
Mitochondrial DNA D-loop AG/TC transition mutation in cortical neurons of mice after long-term exposure to nucleoside analogues.
Topics: Animals; Cerebral Cortex; Didanosine; DNA, Mitochondrial; Lamivudine; Laser Capture Microdissection; Mice; Mice, Inbred BALB C; Mutation; Neurons; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Diagnosis of elephantiasis nostras verrucosa as a clinical mani-festation of Kaposi's sarcoma.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Elephantiasis; Humans; Lamivudine; Male; Middle Aged; Sarcoma, Kaposi | 2020 |
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2016 |
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2016 |